Journal
THORACIC CANCER
Volume 11, Issue 3, Pages 810-818Publisher
WILEY
DOI: 10.1111/1759-7714.13327
Keywords
Immune checkpoint inhibitor; immune-related adverse events (irAEs); ocular toxicities; targeted therapy
Categories
Funding
- CAMS Innovation Fund for Medical Sciences (CIFMS) [2016-I2M-1-002]
Ask authors/readers for more resources
The increased use of targeted therapy and immune checkpoint inhibitors in cancers has brought new hope of survival to patients with advanced tumors. However, increasing numbers of immune-related adverse events (irAEs) of these medications have been reported, affecting almost all human organs including the eye. These adverse effects may affect the entire ocular region, including the eyelid, eye lashes, conjunctiva, cornea, uvea, retina and optic nerve, and have thus far been largely ignored by patients and doctors. In this review, we summarize the characteristics of ocular diseases related to irAEs and advise on how to diagnose and manage these diseases. Key points This review will enable clinical oncologists to recognize, diagnose, and manage targeted therapy and immune checkpoint inhibitor-related ocular adverse events.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available